UK Healthcare Professionals only
Weekly newsletter (optional)
Join the weekly newsletter to receive curated evidence that matters.
Medicine Central
Clinical evidence moves faster than guidelines. Our medical team filters, curates, and reports what has changed and how it impacts primary care practice, so you're always current.
Editor's picks
Rising ADHD referrals means more GPs managing shared-care stimulant prescribing. This week's article is a GP guide to shared-care monitoring, red flags and drug interactions, with a free downloadable cheat sheet.
Surgery still outperforms pharmacotherapy for sustained weight loss. The gap widens once therapy stops. A practical synthesis for UK primary care prescribers.
Dr Frederick Reynolds, a GP using ambient scribes day-to-day, has written the kind of thoughtful, first-hand review these tools deserve.
Type 2 Diabetes
Diagnostic criteria, risk tools, annual care processes and referral pathways.
Chronic Kidney Disease
CKD staging, eGFR monitoring, renal protection and referral pathways.
Obesity
BMI classification, weight management tiers, risk stratification and referral pathways.
Cardiovascular Health
CVD risk assessment, hypertension management, lipid modification and referral pathways.
A UK randomised trial in the largest insulin-treated type 2 cohort that NICE guidelines NG28 doesn't currently fund.
The February 2026 update to NG28 ends that era. Most newly diagnosed patients will now be offered an SGLT-2 inhibitor alongside metformin from the outset.
For over a decade, the question of whether to use apixaban or rivaroxaban for treating acute VTE has remained. The COBRA Trial in NEJM finally provides a head-to-head comparison.
Low-dose multi-drug pills are key and new ways to tackle resistant hypertension are emerging. Since 2022, many Phase III antihypertensive trials have been reported.
When a patient stops a medication, the assumption is usually that the benefits stop too. The EMPA-KIDNEY post-trial follow-up, published in NEJM, checked if this is true for SGLT2 inhibitors in CKD.
The kidney failure risk equation is now in NICE guidance. A new BJGP study from Greater Manchester found that, for most patients, the risk of death is much higher than the risk of needing dialysis.
NICE has now recommended the first drug in a genuinely new class — Fezolinetant in TA1143. It's an NK3 receptor antagonist for moderate to severe menopausal vasomotor symptoms when HRT isn't suitable.
No excess mortality after 14 years. No signal for cardiovascular or cancer deaths; plus a survival benefit in women after bilateral oophorectomy.
How GLP-1 receptor agonists drive weight loss across the brain, gut, and metabolism.
If you prescribe semaglutide, you need to know about this MHRA safety update on the risk of rare vision loss.
The SCOUT trial is the first pragmatic head-to-head comparison of all four commonly used UTI regimens in a single trial. The results reinforce rather than redraw the UK prescribing picture — but they do sharpen one key question for primary care.
The mandate is clear: if a diagnosis remains unsubstantiated or symptoms escalate after three appointments — Reflect, Review, and Rethink. Three strikes and we rethink.
In focus
From semaglutide to tirzepatide: the evidence on weight management medications is moving fast. Our clinical team breaks down what the latest trials mean for prescribing in primary care.
Read the GLP-1 coverage
What the RCGP and Patients Association report means for GP workload, referrals, and NHS digital systems.
For 26 years, NICE has used the same yardstick to decide whether a new medicine is worth funding. From April 2026, that yardstick is changing for the first time, and prescribers will feel it.
Why Medicine Central
Medicine Central is curated especially for UK primary care, with contributions from guest expert clinicians.
Peer-reviewed sources only, with study design and limitations reported alongside the headline.
CPD-eligible webinars let you log time against your appraisal portfolio.
Key publications in 50 words
In 768 Spanish primary care patients with uncomplicated lower UTI, nitrofurantoin 100mg tds for 5 days, pivmecillinam 400mg tds for 3 days, single-dose fosfomycin, and two-dose fosfomycin were compared. Authors concluded nitrofurantoin most effective, single-dose fosfomycin least effective. Open-label design.
This week's edition
This week's key publications, each summarised in 50 words by our clinical team.
Free professional account
We will never share your contact information.
We use cookies to improve your experience and analyse site usage. Strictly necessary cookies are always active. By clicking Accept All, you consent to analytics and performance cookies. Cookie Policy · Privacy Policy
